HOPHD
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, a… Read more
HOPHD (HOPHD) - Net Assets
Latest net assets as of December 2023: $2.78 Million USD
Based on the latest financial reports, HOPHD (HOPHD) has net assets worth $2.78 Million USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.11 Million) and total liabilities ($3.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.78 Million |
| % of Total Assets | 45.55% |
| Annual Growth Rate | 47.03% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 410.54 |
HOPHD - Net Assets Trend (2020–2023)
This chart illustrates how HOPHD's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HOPHD (2020–2023)
The table below shows the annual net assets of HOPHD from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $2.78 Million | -14.26% |
| 2022-12-31 | $3.24 Million | -60.29% |
| 2021-12-31 | $8.17 Million | +832.71% |
| 2020-12-31 | $875.68K | -- |
Equity Component Analysis
This analysis shows how different components contribute to HOPHD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1576922000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $26.62 Million | 944.52% |
| Total Equity | $2.82 Million | 100.00% |
HOPHD Competitors by Market Cap
The table below lists competitors of HOPHD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tritium Dcfc Ltd
OTC:DCFC
|
$11.97K |
|
AB SCIENCE (A8D.SG)
STU:A8D
|
$11.98K |
|
Memex Inc
PINK:MENXF
|
$11.98K |
|
Bayside Corp
PINK:BYSD
|
$12.00K |
|
1399 Internet Technology Application Group Inc
PINK:YSGG
|
$11.96K |
|
AGROSERV MARIUTA
RO:MILK
|
$11.95K |
|
AURION RES
MU:8RA
|
$11.94K |
|
KOOTH PLC LS -05
F:KO0
|
$11.93K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HOPHD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 3,275,428 to 2,818,729, a change of -456,699 (-13.9%).
- Net loss of 6,690,678 reduced equity.
- New share issuances of 5,088,076 increased equity.
- Other factors increased equity by 1,145,903.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.69 Million | -237.37% |
| Share Issuances | $5.09 Million | +180.51% |
| Other Changes | $1.15 Million | +40.65% |
| Total Change | $- | -13.94% |
Book Value vs Market Value Analysis
This analysis compares HOPHD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 517.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 603.60x to 517.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.00 | $1.24 | x |
| 2021-12-31 | $0.01 | $1.24 | x |
| 2022-12-31 | $0.00 | $1.24 | x |
| 2023-12-31 | $0.00 | $1.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HOPHD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -237.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.17x
- Recent ROE (-237.37%) is below the historical average (-163.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -233.74% | 0.00% | 0.00x | 2.99x | $-2.17 Million |
| 2021 | -62.25% | 0.00% | 0.00x | 1.04x | $-5.92 Million |
| 2022 | -121.49% | 0.00% | 0.00x | 2.17x | $-4.31 Million |
| 2023 | -237.37% | 0.00% | 0.00x | 2.17x | $-6.97 Million |
Industry Comparison
This section compares HOPHD's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HOPHD (HOPHD) | $2.78 Million | -233.74% | 1.20x | $11.96K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |